Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
Jyotsna FuloriaOchsner Medical Center, New Orleans, LA, USAAbstract: The biological agents approved for the treatment of patients with metastatic colorectal cancer – bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A, along with cetuximab and panitumum...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-08-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/safety-profiles-of-current-antiangiogenic-therapies-for-metastatic-col-a10730 |